ASH Conf Coverage CheckRare

This year’s American Society of Hematology (ASH) 2018 Annual Meeting was held on December 1-4 in San Diego, California. Physicians, researchers, and health care professionals learned about the latest advances in the treatment of blood cancers and blood disorders. The meeting featured more than 4,400 abstracts, including over 1,000 presented at oral sessions. Many of the reported trials are expected to have an impact on clinical practice.

CheckRare was in attendance and provides some of the conference highlights, focusing on rare diseases.


Sickle Cell Disease: Overview and Emerging Stem Cell Transplant Therapy

Hemophilia: Updated Positive Interim Data from Phase 2/3 Study of Marzeptacog Alfa

Myelodysplastic Syndromes Overview and Personalized Prediction Model for Patients

iPATH Study: Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A

Hereditary TTR Amyloidosis and the NEURO-TTR Study

Venclexta Data Positive for AML

New Treatment Option for Primary Hemophagocytic Lymphohistiocytosis

Management of Hematologic Diseases With Cellular and Immunotherapies

Checkmate 436: Two-Drug Combo Shows Promise for Primary Mediastinal Large B-cell Lymphoma